Answers are grounded in this paper and cite their sources.
Recent innovations in targeted protein degradation (TPD) extend beyond small-molecule PROTACs to encompass engineered peptides and recyclable ligand systems. Two complementary strategiesEGFR-directed peptide complexes and PKC-targeting bifunctional degradershighlight a mechanistic expansion of TPD into kinase-driven pathologies, offering new avenues for addressing cancer resistance, immune dysregulation, and receptor signaling with enhanced precision and modularity.
No takes yet. Share an insight, caveat, or question.
Renner et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: